Markets closed

Cardinal Health, Inc.

CAH · NYSE

Analyst Consensus

Buy

15 analysts

$235

Current

—

Low

$275

Average

—

High

Average target implies +16.82% versus the current price.

Analyst Ratings Synthesis

The consensus rating is Buy across 15 analysts, with a mean price target of $256.50 versus Cardinal Health’s latest supplied close of $233.55. The low and high targets are unavailable, so target clustering and the breadth of the spread cannot be measured. The evidence does not identify which analyst is most bullish or least bullish because no individual ratings, targets, or named analyst views are supplied. It also reports no rating or target revisions during the past week, leaving revision direction undetermined. Consequently, the substantive disagreement behind the target distribution cannot be assessed; the available evidence supports only a broad positive consensus and a mean target above the market price.

Rating Actions

No individual rating actions have been captured for CAHyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

CITIGROUP

CO FORECST

DEUTSCHE BK SEC

EVERCORE ISI

JEFFERIES & CO.

JP MORGAN SECUR

MIZUHO SECURITI

MORGAN STANLEY

TD COWEN

UBS

WELLS FARGO SEC

ZACKS RESEARCH

Symbol: CAH
Type: Stock
Sector: Health Care
Industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Exchange: NYSE

Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day.

Key Issues

Bullish view

Zacks says Cardinal has the right combination of two key ingredients for a likely beat, while Wall Street expects earnings growth in the upcoming report.

Bearish view

The supplied evidence contains expectations rather than reported results, so there is no confirmed beat, guidance increase, or operating detail to validate the bullish setup.

Analyst Consensus

See all

Buy

15 analysts

$235

Current

—

Low

$275

Average

—

High

Average target implies +16.82% versus the current price.

Earnings History

BeatMissNo estimate

Cardinal Health, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers